you have triewd for years to tell us how MAKO is the next ISRG

You obviously have me confused with someone else ... or, as was the case, you are just making things up to suit your preconceptions.

Go ahead and find the data yourself since you question it.

I think the burden is on you to find relevant data. Comparing the two at the present time is clearly inappropriate, so to make a contention that there is even a difference, we need relevant data.

Of course, one doesn't know the future of MAKO ... otherwise investing would be a lot easier ... but that doesn't keep one from putting academic or general adoption curves side by side and comparing adoption from date of release. And, as I said, one should look at the whole curve since it may be that ISRG had some early advantage because of the ED issue that would not carry over into later indications.

The point is that you are making assertions of how poorly MAKO has done in comparison and are providing no relevant data to support that assertion. Seems likely, even, that MAKO is not being adopted as quickly, but that doesn't make them a failure.